Chemotherapy for patients with advanced gastric cancer with performance status 2

Gastrointestinal Cancer Research

Volumn 3, Issue 6, 2010, Pages 14-18

  Shitara, Kohei ^a   Muro, Kei ^a   Matsuo, Keitaro ^a   Ura, Takashi ^a   Takahari, Daisuke ^a   Yokota, Tomoya ^a   Sawaki, Akira ^a   Kawai, Hiroki ^a   Ito, Seiji ^a   Munakata, Masaki ^b   Sakata, Yuh ^b  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b Misawa City Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; IRINOTECAN; PACLITAXEL; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASCITES; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; DIARRHEA; DRUG TOXICITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PERFORMANCE; PROGNOSIS; RETROSPECTIVE STUDY; SIDE EFFECT; STOMACH CANCER; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

EID: 77958111478     PISSN: 19347820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Buonadonna A, Lombardi D, De Paoli A, et al: Adenocarcinoma of the stomach: univariate and multivariate analyses of factors associated with survival. Tumori 2:S31-S34, 2003
2. Chau I, Norman AR, Cunningham D, et al: Multivariate prognostic factor analysis in locally advanced and metastatic esophagogastric cancer pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 22:2395-2403, 2004
3. Boku N, Yamamoto S, Shirao K, et al: Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). J Clin Oncol 25:18s, 2007 (supple; abstr LBA4513)
4. Koizumi W, Narahara H, Hara T, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215-221, 2008
5. Chin K, Ishi H, Imamura H, et al: Irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer: Preliminary results of a randomized phase III study (GC0301/TOP-002). J Clin Oncol 25:18s, 2007 (supple; abstr 4525)
6. Van Cutsem E, Moiseyenko EM, Tjulandin S, et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991-4997, 2006
7. Cunningham D, Starling N, Rao, S, et al: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36-46, 2008
8. Ajani JA, Rodriguez W, Bodoky G, et al: Multi center phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS). 2009 Gastrointestinal Cancers Symposium. (abstr 8)
9. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
10. Futatsuki K, Wakui A, Nakao I, et al: Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastro intestinal Cancer Study Group. Gan To Kagaku Ryoho 21:1033-1038, 1994
11. Taguchi T, Sakata Y, Kanamaru R, et al: Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A). Gan To Kagaku Ryoho 25:1915-1924, 1998
12. Hironaka S, Zenda S, Boku N, et al: Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 9:14-18, 2006
13. Yamao T, Shimada Y, Shirao K, et al: Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Trial. Jpn J Clin Oncol 34:316-322, 2004
14. Yamaguchi K, Tada M, Horikoshi N, et al: Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer 5:90-95, 2002
15. Ohtsu A, Shimada Y, Shirao K, et al: Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21:54-59, 2003
16. Okines AF, Norman AR, McCloud P, et al: Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol [Epub ahead of print] May 27, 2009
17. Kang YK, Kang WK, Shin DB, et al: Cape citabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 20:666-673, 2009
18. Jeung HC, Rha SY, Shin SJ, et al: A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status. Br J Cancer 97:458-463, 2007
19. Shirao K, Boku N, Yamada Y, et al: Randomized phase III study of 5-fluorouracil continuous infusion (5FUci) versus methotrex-ate and 5-FU sequential therapy (MF) in gastric cancer with peritoneal metastasis (JCOG0106). J Clin Oncol 27:15s, 2009 (suppl; abstr 4545)